Get the Stockscreener App
7.885
0.13%
0.005
Vigil Neuroscience Inc stock is traded at $7.885, with a volume of 1.75M.
It is up +0.13% in the last 24 hours and up +226.03% over the past month.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
See More
Previous Close:
$7.88
Open:
$7.89
24h Volume:
1.75M
Relative Volume:
1.87
Market Cap:
$370.11M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-3.8277
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
-0.50%
1M Performance:
+226.03%
6M Performance:
+247.58%
1Y Performance:
+71.52%
1-Day Range:
$7.85
$7.90
1-Week Range:
$7.85
$7.94
52-Week Range:
$1.312
$7.95
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
7.885 | 370.11M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.80 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
502.00 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.88 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
583.64 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.27 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - TradingView
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - PR Newswire
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Trial | VIGL Stock News - GuruFocus
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - marketscreener.com
Clinical Setback: Vigil Neuroscience Halts Phase 2 ALSP Trial After Iluzanebart Shows No Efficacy - Stock Titan
Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Tria - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - sharewise
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The MergerPRA, AXL, SWTX and VIGL - The Malaysian Reserve
HC Wainwright Has Bearish Estimate for VIGL FY2026 Earnings - Defense World
Sanofi to acquire Vigil Neuroscience in $470-M deal - MSN
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold - Defense World
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - The Globe and Mail
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL St - GuruFocus
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL Stock News - GuruFocus
France: Sanofi adding to neurology pipeline with acquisition of Vigil Neuroscience - Investors in Healthcare
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by HC Wainwright to “Neutral” - Defense World
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 - Investing.com Australia
VIGL: HC Wainwright Downgrades Vigil Neuroscience, Lowers Price Target | VIGL Stock News - GuruFocus
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 By Investing.com - Investing.com India
Vigil Neuroscience (VIGL) Downgraded by Stifel Following Sanofi Deal | VIGL Stock News - GuruFocus
Vigil Neuroscience (VIGL) Downgraded Amid Acquisition Plans | VIGL Stock News - GuruFocus
Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments - TipRanks
HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8 - marketscreener.com
Wedbush Equities Analysts Reduce Earnings Estimates for VIGL - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Price Target from Brokerages - Defense World
Vigil Neuroscience Elects Directors at Annual Meeting - MSN
Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to “Hold” at Mizuho - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Cut to “Hold” at Guggenheim - Defense World
Vigil Neuroscience’s (VIGL) “Market Perform” Rating Reiterated at JMP Securities - Defense World
Sanofi to Acquire Vigil Neuroscience for Up to $600M in Alzheimer’s Drug Push - USA Herald
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Financial Post
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade - MSN
Vigil Neuroscience shareholders approve board nominees By Investing.com - Investing.com South Africa
Vigil Neuroscience Inc (VIGL) was downgraded to a Hold Rating at Mizuho Securities - The Globe and Mail
Vigil Neuroscience shareholders approve board nominees - Investing.com Australia
Mizuho cuts Vigil Neuroscience stock rating to neutral By Investing.com - Investing.com Nigeria
Mizuho cuts Vigil Neuroscience stock rating to neutral - Investing.com Australia
Sanofi to spend $470M for Watertown biotech’s Alzheimer’s drug - The Business Journals
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline - Pharmafile
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vigil Neuroscience Inc Stock (VIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
1.47%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):